180 related articles for article (PubMed ID: 37253096)
1. Prognostic evaluation of re-resection for recurrent glioblastoma using the novel RANO classification for extent of resection: A report of the RANO resect group.
Karschnia P; Dono A; Young JS; Juenger ST; Teske N; Häni L; Sciortino T; Mau CY; Bruno F; Nunez L; Morshed RA; Haddad AF; Weller M; van den Bent M; Beck J; Hervey-Jumper S; Molinaro AM; Tandon N; Rudà R; Vogelbaum MA; Bello L; Schnell O; Grau SJ; Chang SM; Berger MS; Esquenazi Y; Tonn JC
Neuro Oncol; 2023 Sep; 25(9):1672-1685. PubMed ID: 37253096
[TBL] [Abstract][Full Text] [Related]
2. Prognostic validation of a new classification system for extent of resection in glioblastoma: A report of the RANO resect group.
Karschnia P; Young JS; Dono A; Häni L; Sciortino T; Bruno F; Juenger ST; Teske N; Morshed RA; Haddad AF; Zhang Y; Stoecklein S; Weller M; Vogelbaum MA; Beck J; Tandon N; Hervey-Jumper S; Molinaro AM; Rudà R; Bello L; Schnell O; Esquenazi Y; Ruge MI; Grau SJ; Berger MS; Chang SM; van den Bent M; Tonn JC
Neuro Oncol; 2023 May; 25(5):940-954. PubMed ID: 35961053
[TBL] [Abstract][Full Text] [Related]
3. Surgical management and outcome of newly diagnosed glioblastoma without contrast enhancement (low-grade appearance): a report of the RANO resect group.
Karschnia P; Dietrich J; Bruno F; Dono A; Juenger ST; Teske N; Young JS; Sciortino T; Häni L; van den Bent M; Weller M; Vogelbaum MA; Morshed RA; Haddad AF; Molinaro AM; Tandon N; Beck J; Schnell O; Bello L; Hervey-Jumper S; Thon N; Grau SJ; Esquenazi Y; Rudà R; Chang SM; Berger MS; Cahill DP; Tonn JC
Neuro Oncol; 2024 Jan; 26(1):166-177. PubMed ID: 37665776
[TBL] [Abstract][Full Text] [Related]
4. Supramaximal resection: retrospective study on IDH-wildtype Glioblastomas based on the new RANO-Resect classification.
Tropeano MP; Raspagliesi L; Bono BC; Baram A; Rossini Z; Franzini A; Navarria P; Clerici E; Bellu L; Simonelli M; Scorsetti M; Riva M; Politi LS; Pessina F
Acta Neurochir (Wien); 2024 Apr; 166(1):196. PubMed ID: 38676720
[TBL] [Abstract][Full Text] [Related]
5. Impact of extent of resection on outcome from glioblastoma using the RANO resect group classification system: a retrospective, population-based cohort study.
Bjorland LS; Mahesparan R; Fluge Ø; Gilje B; Dæhli Kurz K; Farbu E
Neurooncol Adv; 2023; 5(1):vdad126. PubMed ID: 37868696
[TBL] [Abstract][Full Text] [Related]
6. Refinement of response assessment in neuro-oncology (RANO) using non-enhancing lesion type and contrast enhancement evolution pattern in IDH wild-type glioblastomas.
Moon HH; Kim HS; Park JE; Kim YH; Kim JH
BMC Cancer; 2021 Jun; 21(1):654. PubMed ID: 34074252
[TBL] [Abstract][Full Text] [Related]
7. Association of Maximal Extent of Resection of Contrast-Enhanced and Non-Contrast-Enhanced Tumor With Survival Within Molecular Subgroups of Patients With Newly Diagnosed Glioblastoma.
Molinaro AM; Hervey-Jumper S; Morshed RA; Young J; Han SJ; Chunduru P; Zhang Y; Phillips JJ; Shai A; Lafontaine M; Crane J; Chandra A; Flanigan P; Jahangiri A; Cioffi G; Ostrom Q; Anderson JE; Badve C; Barnholtz-Sloan J; Sloan AE; Erickson BJ; Decker PA; Kosel ML; LaChance D; Eckel-Passow J; Jenkins R; Villanueva-Meyer J; Rice T; Wrensch M; Wiencke JK; Oberheim Bush NA; Taylor J; Butowski N; Prados M; Clarke J; Chang S; Chang E; Aghi M; Theodosopoulos P; McDermott M; Berger MS
JAMA Oncol; 2020 Apr; 6(4):495-503. PubMed ID: 32027343
[TBL] [Abstract][Full Text] [Related]
8. Initial surgical resection and long time to occurrence from initial diagnosis are independent prognostic factors in resected recurrent IDH wild-type glioblastoma.
Seyve A; Lozano-Sanchez F; Thomas A; Mathon B; Tran S; Mokhtari K; Giry M; Marie Y; Capelle L; Peyre M; Carpentier A; Feuvret L; Sanson M; Hoang-Xuan K; Honnorat J; Delattre JY; Ducray F; Idbaih A
Clin Neurol Neurosurg; 2020 Sep; 196():106006. PubMed ID: 32554237
[TBL] [Abstract][Full Text] [Related]
9. Response Assessment in Neuro-Oncology criteria, contrast enhancement and perfusion MRI for assessing progression in glioblastoma.
Tensaouti F; Khalifa J; Lusque A; Plas B; Lotterie JA; Berry I; Laprie A; Cohen-Jonathan Moyal E; Lubrano V
Neuroradiology; 2017 Oct; 59(10):1013-1020. PubMed ID: 28842741
[TBL] [Abstract][Full Text] [Related]
10. Extending the resection beyond the contrast-enhancement for glioblastoma: feasibility, efficacy, and outcomes.
Mampre D; Ehresman J; Pinilla-Monsalve G; Osorio MAG; Olivi A; Quinones-Hinojosa A; Chaichana KL
Br J Neurosurg; 2018 Oct; 32(5):528-535. PubMed ID: 30073866
[TBL] [Abstract][Full Text] [Related]
11. Supramaximal Resection for Glioblastoma: Redefining the Extent of Resection Criteria and Its Impact on Survival.
Roh TH; Kim SH
Brain Tumor Res Treat; 2023 Jul; 11(3):166-172. PubMed ID: 37550815
[TBL] [Abstract][Full Text] [Related]
12. Comparison of 2D (RANO) and volumetric methods for assessment of recurrent glioblastoma treated with bevacizumab-a report from the BELOB trial.
Gahrmann R; van den Bent M; van der Holt B; Vernhout RM; Taal W; Vos M; de Groot JC; Beerepoot LV; Buter J; Flach ZH; Hanse M; Jasperse B; Smits M
Neuro Oncol; 2017 Jun; 19(6):853-861. PubMed ID: 28204639
[TBL] [Abstract][Full Text] [Related]
13. Residual tumor volume versus extent of resection: predictors of survival after surgery for glioblastoma.
Grabowski MM; Recinos PF; Nowacki AS; Schroeder JL; Angelov L; Barnett GH; Vogelbaum MA
J Neurosurg; 2014 Nov; 121(5):1115-23. PubMed ID: 25192475
[TBL] [Abstract][Full Text] [Related]
14. Association of Neurological Impairment on the Relative Benefit of Maximal Extent of Resection in Chemoradiation-Treated Newly Diagnosed Isocitrate Dehydrogenase Wild-Type Glioblastoma.
Aabedi AA; Young JS; Zhang Y; Ammanuel S; Morshed RA; Dalle Ore C; Brown D; Phillips JJ; Oberheim Bush NA; Taylor JW; Butowski N; Clarke J; Chang SM; Aghi M; Molinaro AM; Berger MS; Hervey-Jumper SL
Neurosurgery; 2022 Jan; 90(1):124-130. PubMed ID: 34982879
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors influencing survival following re-resection for isocitrate dehydrogenase (IDH) -wildtype glioblastoma multiforme - Data from a national neuro-oncology registry.
Hennessy MA; Coyne ZL; O'Halloran PJ; Mullally W; Dablouk M; MacNally S; Morris PG
J Clin Neurosci; 2022 Jan; 95():142-150. PubMed ID: 34929638
[TBL] [Abstract][Full Text] [Related]
16. Associations between recurrence patterns and outcome in glioblastoma patients undergoing re-resection: A complementary report of the RANO resect group.
Karschnia P; Dono A; Young JS; Juenger ST; Teske N; Häni L; Sciortino T; Mau CY; Bruno F; Nunez L; Morshed RA; Haddad AF; Weller M; van den Bent M; Thon N; Beck J; Hervey-Jumper S; Molinaro AM; Tandon N; Rudà R; Vogelbaum MA; Bello L; Schnell O; Grau SJ; Chang SM; Berger MS; Esquenazi Y; Tonn JC
Neuro Oncol; 2024 Mar; 26(3):584-586. PubMed ID: 38164632
[No Abstract] [Full Text] [Related]
17. DNA methylation subclasses predict the benefit from gross total tumor resection in IDH-wildtype glioblastoma patients.
Drexler R; Schüller U; Eckhardt A; Filipski K; Hartung TI; Harter PN; Divé I; Forster MT; Czabanka M; Jelgersma C; Onken J; Vajkoczy P; Capper D; Siewert C; Sauvigny T; Lamszus K; Westphal M; Dührsen L; Ricklefs FL
Neuro Oncol; 2023 Feb; 25(2):315-325. PubMed ID: 35868257
[TBL] [Abstract][Full Text] [Related]
18. Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma-results from the DIRECTOR trial.
Suchorska B; Weller M; Tabatabai G; Senft C; Hau P; Sabel MC; Herrlinger U; Ketter R; Schlegel U; Marosi C; Reifenberger G; Wick W; Tonn JC; Wirsching HG
Neuro Oncol; 2016 Apr; 18(4):549-56. PubMed ID: 26823503
[TBL] [Abstract][Full Text] [Related]
19. Recurrent pseudoprogression in isocitrate dehydrogenase 1 mutant glioblastoma.
Kebir S; Rauschenbach L; Gielen GH; Schäfer N; Tzaridis T; Scheffler B; Giordano FA; Lazaridis L; Herrlinger U; Glas M
J Clin Neurosci; 2018 Jul; 53():255-258. PubMed ID: 29754968
[TBL] [Abstract][Full Text] [Related]
20. Clinical benefit from resection of recurrent glioblastomas: results of a multicenter study including 503 patients with recurrent glioblastomas undergoing surgical resection.
Ringel F; Pape H; Sabel M; Krex D; Bock HC; Misch M; Weyerbrock A; Westermaier T; Senft C; Schucht P; Meyer B; Simon M;
Neuro Oncol; 2016 Jan; 18(1):96-104. PubMed ID: 26243790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
